EXPLORING HIDDEN SURVIVAL HETEROGENEITY AMONG FIRST-LINE (1L) INTERMEDIATE/POOR (I/P)-RISK ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VIA PARAMETRIC MIXTURE MODELS (PMM)

被引：0
|
作者：
Hunger, M. [1 ]
George, S. [2 ]
Dyer, M. [3 ]
Ejzykowicz, F. [4 ]
May, J. R. [3 ]
Kurt, M. [5 ]
机构：
[1] ICON Plc, Munich, Germany
[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[3] Bristol Myers Squibb, Uxbridge, Middx, England
[4] Bristol Myers Squibb, Lawrenceville, NJ USA
[5] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MSR54
引用
收藏
页码：S287 / S287
页数：1
相关论文
共 50 条
  • [21] QUALITY ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE PROGRESSION OR TOXICITY (Q-TWIST) OF NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VS SUNITINIB (SUN) AMONG UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS (PATIENTS) WITH INTERMEDIATE OR POOR PROGNOSTIC RISK
    Shah, R.
    Botteman, M.
    Kwon, Y.
    Gooden, K. M.
    Cella, D.
    Motzer, R.
    VALUE IN HEALTH, 2019, 22 : S106 - S106
  • [22] Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
    Ali, Sana
    Leong, Sally
    Meza, Luis A.
    Dizman, Nazli
    Zengin, Zeynep Busra
    Kim, Tane
    Pak, Youngju
    Onyshchenko, Mykola
    Pal, Sumanta K.
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Cakar, Esra
    Oniangue-Ndza, Cesar
    Schneider, Ralph P. P.
    Klijn, Sven L. L.
    Vogl, Ursula M. M.
    Rothermundt, Christian
    May, Jessica R. R.
    PHARMACOECONOMICS-OPEN, 2023, 7 (04) : 567 - 577
  • [24] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Esra Çakar
    César Oniangue-Ndza
    Ralph P. Schneider
    Sven L. Klijn
    Ursula M. Vogl
    Christian Rothermundt
    Jessica R. May
    PharmacoEconomics - Open, 2023, 7 : 567 - 577
  • [25] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) plus chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA
    John, T.
    Sakai, H.
    Ikeda, S.
    Cheng, Y.
    Kasahara, K.
    Sato, Y.
    Nakahara, Y.
    Takeda, M.
    Kaneda, H.
    Zhang, H.
    Maemondo, M.
    Minato, K.
    Hisada, T.
    Misumi, Y.
    Satouchi, M.
    Hotta, K.
    Li, A.
    Oukessou, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S847 - S848
  • [26] Nivolumab plus ipilimumab (NIVO plus IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial
    Escudier, Bernard
    Mcdermott, David F.
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Atkins, Michael B.
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Rini, Brian I.
    Jiang, Ruiyun
    Desilva, Heshani
    Lee, Chung-Wei
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 363 - 363
  • [27] Pembrolizumab plus lenvatinib (P plus L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
    Yan, Kevin
    Rane, Pratik
    Schmidinger, Manuela
    Peer, Avivit
    Druyts, Eric
    Burgents, Joseph E.
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 422 - 422
  • [28] Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I/P) prognostic risk
    Choueiri, T. K.
    Stwalley, B.
    Huo, S.
    May, J. R.
    Malcolm, B.
    Nickel, K.
    Szabo, N.
    Klijn, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S563 - S564
  • [29] Pembrolizumab plus lenvatinib (P plus L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
    Rane, Pratik
    Yan, Kevin
    Schmidinger, Manuela
    Peer, Avivit
    Druyts, Eric
    Burgents, Joseph E.
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 421 - 421
  • [30] Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Plimack, E. R.
    Porta, C. G.
    George, S.
    Powles, T. B.
    Donskov, F.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M-O.
    Tomita, Y.
    Rini, B. I.
    McHenry, M. B.
    Lee, C-W.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S685 - S687
12345